Equities research analysts expect that Repligen Co. (NASDAQ:RGEN) will post $0.12 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have issued estimates for Repligen’s earnings. The lowest EPS estimate is $0.11 and the highest is $0.13. Repligen reported earnings per share of $0.08 in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The company is scheduled to announce its next earnings report before the market opens on Thursday, February 22nd.

On average, analysts expect that Repligen will report full-year earnings of $0.61 per share for the current year, with EPS estimates ranging from $0.60 to $0.63. For the next financial year, analysts expect that the business will post earnings of $0.71 per share, with EPS estimates ranging from $0.68 to $0.75. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Repligen.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.04. The business had revenue of $36.58 million during the quarter, compared to analyst estimates of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm’s quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the business earned $0.08 EPS.

RGEN has been the subject of a number of research reports. First Analysis upgraded shares of Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday, October 5th. Jefferies Group reiterated a “hold” rating and issued a $40.00 price objective on shares of Repligen in a report on Thursday, October 19th. CL King initiated coverage on shares of Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price objective for the company. Finally, TheStreet downgraded shares of Repligen from a “b-” rating to a “c” rating in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $44.38.

Shares of Repligen (NASDAQ:RGEN) traded down $1.21 during midday trading on Thursday, reaching $35.94. 293,518 shares of the company were exchanged, compared to its average volume of 213,269. The company has a market cap of $1,607.12, a price-to-earnings ratio of 60.92, a PEG ratio of 2.07 and a beta of 1.04. Repligen has a 1-year low of $28.69 and a 1-year high of $46.81.

In other Repligen news, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total transaction of $322,471.50. Following the completion of the sale, the chief executive officer now owns 83,613 shares of the company’s stock, valued at approximately $3,005,887.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the sale, the vice president now directly owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in RGEN. Lord Abbett & CO. LLC increased its position in Repligen by 330.9% during the 2nd quarter. Lord Abbett & CO. LLC now owns 851,360 shares of the biotechnology company’s stock valued at $35,280,000 after purchasing an additional 653,791 shares during the period. PointState Capital LP acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $11,984,000. Conestoga Capital Advisors LLC grew its position in shares of Repligen by 14.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,669,562 shares of the biotechnology company’s stock worth $60,572,000 after buying an additional 216,330 shares during the period. Macquarie Group Ltd. grew its position in shares of Repligen by 34.6% during the 3rd quarter. Macquarie Group Ltd. now owns 752,433 shares of the biotechnology company’s stock worth $28,833,000 after buying an additional 193,232 shares during the period. Finally, Castleark Management LLC acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $7,592,000. 83.68% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/30/0-12-eps-expected-for-repligen-co-rgen-this-quarter.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.